PMID- 35041577
OWN - NLM
STAT- MEDLINE
DCOM- 20220228
LR  - 20220228
IS  - 1473-5644 (Electronic)
IS  - 0022-2615 (Linking)
VI  - 71
IP  - 1
DP  - 2022 Jan
TI  - Comparison of sequential therapy with concomitant therapy in first-line treatment 
      of Helicobacter pylori: an updated meta-analysis.
LID - 10.1099/jmm.0.001490 [doi]
AB  - Sequential therapy (ST) and concomitant therapy (CT) are common first-line 
      treatments for Helicobacter pylori (HP). This study aimed to assess the 
      efficiency and safety of ST and CT in the first-line treatment of HP by comparing 
      their clinical outcomes. Two authors independently searched PubMed, EBSCO, Web of 
      Science and the Cochrane Library for all the relevant articles published before 
      March 2021 to compare the clinical outcomes of HP patients undergoing ST or CT. 
      The primary outcome measures were HP eradication rates and adverse events (AEs). 
      This meta-analysis included 24 articles with 7531 HP patients. CT was better than 
      ST in eradicating HP from per-protocol analysis (PP) (RR=0.96, P<0.001) and 
      modified intent-to-treat analysis (MITT) (RR=0.94, P=0.005). Compared with 
      non-Asia, CT demonstrated more apparent advantages than ST in Asia. CT treated 
      with lansoprazole, pantoprazole and esomeprazole outperformed ST treated with the 
      same PPIs. CT for 10 days and ST for 14 days were the better choices of course of 
      treatment. The incidence rates of AEs were significantly higher in CT than in ST 
      for diarrhoea (RR=0.65, P<0.001), vomiting (RR=0.68, P=0.03), dysgeusia (RR=0.83, 
      P=0.03) and dizziness (RR=0.77, P=0.05). Both ST and CT are safe and effective 
      first-line treatments for HP. Although the AEs were more frequent with CT than 
      ST, CT was superior to ST, especially in Asia. The effect of various PPIs varied 
      in various therapies. The best course of treatment was 10 days for CT and 14 days 
      for ST.
FAU - Wang, Keliang
AU  - Wang K
AD  - Department of Gastroenterology, HwaMei Hospital, University of Chinese Academy of 
      Sciences, Ningbo, Zhejiang, PR China.
AD  - Ningbo Institute of Life and Health Industry, University of Chinese Academy of 
      Sciences, Ningbo, PR China.
FAU - Lou, Dandi
AU  - Lou D
AD  - The First Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, PR China.
FAU - Dai, Wei
AU  - Dai W
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, PR China.
FAU - Fu, Rongrong
AU  - Fu R
AD  - The First Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, PR China.
FAU - Ma, Zhenhua
AU  - Ma Z
AD  - Department of Gastroenterology, HwaMei Hospital, University of Chinese Academy of 
      Sciences, Ningbo, Zhejiang, PR China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - J Med Microbiol
JT  - Journal of medical microbiology
JID - 0224131
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Amoxicillin/therapeutic use
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Clarithromycin/therapeutic use
MH  - Drug Therapy, Combination
MH  - *Helicobacter Infections/drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - *Proton Pump Inhibitors/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - concomitant therapy
OT  - eradication rates
OT  - meta-analysis
OT  - sequential therapy
EDAT- 2022/01/19 06:00
MHDA- 2022/03/01 06:00
CRDT- 2022/01/18 17:19
PHST- 2022/01/18 17:19 [entrez]
PHST- 2022/01/19 06:00 [pubmed]
PHST- 2022/03/01 06:00 [medline]
AID - 10.1099/jmm.0.001490 [doi]
PST - ppublish
SO  - J Med Microbiol. 2022 Jan;71(1). doi: 10.1099/jmm.0.001490.